文献速递冠心病

载脂蛋白A-I输注与急性心肌梗死后心血管结局:AEGIS-II试验按基线LDL-C水平分析

Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial.
PubMed 文献 · Eur Heart J · 2024-01-01

AEGIS-II试验事后分析纳入15 731例接受指南导向他汀治疗的急性心梗患者,评估CSL112(血浆来源载脂蛋白A1)疗效是否受基线LDL-C影响。基线LDL-C≥100 mg/dL者,CSL112较安慰剂显著降低90天、180天和365天心血管死亡、心梗或卒中风险;LDL-C<100 mg/dL者两组无差异。

要点

  • 基线LDL-C≥100 mg/dL的急性心梗患者,CSL112降低90天主要终点风险。
  • LDL-C≥100 mg/dL者180天和365天心血管死亡、心梗或卒中风险亦显著降低。
  • 基线LDL-C<100 mg/dL者,CSL112与安慰剂无差异。

核心结论

  • 在急性心梗且接受指南导向他汀治疗的患者中,CSL112较安慰剂与基线LDL-C≥100 mg/dL者复发性心血管事件风险显著降低相关。

研究设计与样本

  • AEGIS-II(NCT03473223)为随机试验,18 219例急性心梗、多支冠状动脉病变且合并额外危险因素患者随机接受每周四次6 g CSL112或安慰剂输注。
  • 本分析为探索性事后分析,按随机时基线LDL-C评估接受指南导向他汀治疗患者(n=15 731)的心血管结局。

主要发现

  • 随基线LDL-C升高,CSL112组较安慰剂组90天主要终点风险降低。
  • 基线LDL-C<100 mg/dL者,两治疗组间无差异。

临床怎么用

  • 对于急性心梗后接受指南导向他汀治疗且基线LDL-C≥100 mg/dL的患者,CSL112可能降低复发性心血管事件风险,但需进一步研究确认其疗效受基线LDL-C影响。

局限性

  • 本分析为探索性事后分析,需进一步研究确认CSL112疗效受基线LDL-C影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days vs. placebo after acute myocardial infarction (MI). Nevertheless, given the well-established relationship between higher low-density lipoprotein cholesterol (LDL-C) and plaque burden, as well as greater risk reductions seen with PCSK9 inhibitors in patients with baseline LDL-C ≥ 100 mg/dL on statin therapy, the efficacy of CSL112 may be influenced by baseline LDL-C. METHODS: Overall, 18 219 patients with acute MI, multivessel coronary artery disease, and additional risk factors were randomized to either four weekly infusions of 6 g CSL112 or placebo. This exploratory post-hoc analysis evaluated cardiovascular outcomes by baseline LDL-C in patients prescribed guideline-directed statin therapy at the time of randomization (n = 15 731). RESULTS: As baseline LDL-C increased, the risk of the primary endpoint at 90 days lowered in those treated with CSL112 compared with placebo. In patients with LDL-C ≥ 100 mg/dL at randomization, there was a significant risk reduction of cardiovascular death, MI, or stroke in the CSL112 vs. placebo group at 90, 180, and 365 days [hazard ratio .69 (.53-.90), .71 (.57-.88), and .78 (.65-.93)]. In contrast, there was no difference between treatment groups among those with LDL-C < 100 mg/dL at baseline. CONCLUSIONS: In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥ 100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Gibson, Duffy, Bahit, et al. Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial. Eur Heart J. 2024. PMID: 39221651. doi:10.1093/eurheartj/ehae614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。